BRPI0818846A2 - Rna de fita dupla modificado por lipídeo tendo potente efeito de rna de interferência. - Google Patents
Rna de fita dupla modificado por lipídeo tendo potente efeito de rna de interferência.Info
- Publication number
- BRPI0818846A2 BRPI0818846A2 BRPI0818846A BRPI0818846A2 BR PI0818846 A2 BRPI0818846 A2 BR PI0818846A2 BR PI0818846 A BRPI0818846 A BR PI0818846A BR PI0818846 A2 BRPI0818846 A2 BR PI0818846A2
- Authority
- BR
- Brazil
- Prior art keywords
- rna
- effect
- modified double
- lipid modified
- stranded rna
- Prior art date
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 150000002632 lipids Chemical class 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007276985 | 2007-10-24 | ||
| PCT/JP2008/069829 WO2009054551A2 (en) | 2007-10-24 | 2008-10-24 | Lipid-modified double-stranded rna having potent rna interference effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0818846A2 true BRPI0818846A2 (pt) | 2015-04-14 |
Family
ID=40524987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0818846 BRPI0818846A2 (pt) | 2007-10-24 | 2008-10-24 | Rna de fita dupla modificado por lipídeo tendo potente efeito de rna de interferência. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8981074B2 (pt) |
| EP (1) | EP2217284A2 (pt) |
| JP (2) | JP5887648B2 (pt) |
| KR (1) | KR20100106314A (pt) |
| CN (2) | CN101835497A (pt) |
| AR (1) | AR069019A1 (pt) |
| AU (1) | AU2008314860B2 (pt) |
| BR (1) | BRPI0818846A2 (pt) |
| CA (1) | CA2703496A1 (pt) |
| CO (1) | CO6270240A2 (pt) |
| IL (1) | IL204992A (pt) |
| MX (1) | MX2010004452A (pt) |
| NZ (1) | NZ584509A (pt) |
| RU (1) | RU2489167C2 (pt) |
| SG (1) | SG185295A1 (pt) |
| TW (1) | TW200927177A (pt) |
| UA (1) | UA104131C2 (pt) |
| WO (1) | WO2009054551A2 (pt) |
| ZA (1) | ZA201002427B (pt) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100047909A1 (en) * | 2007-03-02 | 2010-02-25 | Mdrna, Inc. | Nucleic acid compounds for inhibiting vegf family gene expression and uses thereof |
| ES2605618T3 (es) | 2008-03-31 | 2017-03-15 | National Institute Of Advanced Industrial Science And Technology | ARN de doble cadena, modificado con lípidos con elevado efecto de interferencia por ARN |
| KR101224828B1 (ko) * | 2009-05-14 | 2013-01-22 | (주)바이오니아 | ｓｉＲＮＡ 접합체 및 그 제조방법 |
| GB0910723D0 (en) | 2009-06-22 | 2009-08-05 | Sylentis Sau | Novel drugs for inhibition of gene expression |
| EP2857513A4 (en) * | 2012-05-26 | 2016-05-25 | Bonac Corp | Single-stranded nucleic acid molecule controlling the expression of a gene transporter |
| RU2523119C2 (ru) * | 2012-09-28 | 2014-07-20 | Общество с ограниченной ответственностью "ВИТАЛАНГ" | Способ количественной оценки эффективности олеиновой кислоты как переносчика рнк через биологические мембраны |
| US10612020B2 (en) | 2013-12-26 | 2020-04-07 | Tokyo Medical University | Artificial mimic miRNA for controlling gene expression, and use of same |
| BR112016014986A2 (pt) | 2013-12-27 | 2018-01-23 | Bonac Corporation | mirna tipo correspondência artificial, composição e método para suprimir expressão de um gene alvo, composição farmacêutica, método para tratar uma doença, e, ácido nucleico de fita única |
| RU2740032C2 (ru) | 2014-12-27 | 2020-12-30 | Бонак Корпорейшн | ВСТРЕЧАЮЩИЕСЯ В ПРИРОДЕ миРНК ДЛЯ КОНТРОЛИРОВАНИЯ ЭКСПРЕССИИ ГЕНОВ И ИХ ПРИМЕНЕНИЕ |
| HK1244031A1 (en) | 2015-03-27 | 2018-07-27 | Bonac Corporation | Single-chain nucleic acid molecule having delivery function and gene expression control ability |
| US9809817B2 (en) | 2015-04-03 | 2017-11-07 | University Of Massachusetts | Oligonucleotide compounds for targeting huntingtin mRNA |
| EP3929293A3 (en) | 2015-04-03 | 2022-03-16 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| EP3334499A4 (en) | 2015-08-14 | 2019-04-17 | University of Massachusetts | BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES |
| CA3011894A1 (en) | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| US11753638B2 (en) | 2016-08-12 | 2023-09-12 | University Of Massachusetts | Conjugated oligonucleotides |
| RU2019119833A (ru) | 2016-11-28 | 2020-12-29 | Нападжен Фарма, Инк. | ХИМИЧЕСКИ МОДИФИЦИРОВАННАЯ миРНК |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| CN110799647A (zh) | 2017-06-23 | 2020-02-14 | 马萨诸塞大学 | 双尾自递送sirna及相关的方法 |
| JP7208911B2 (ja) * | 2017-10-11 | 2023-01-19 | 日東電工株式会社 | 核酸分子発現の調節 |
| BR112020022546A8 (pt) | 2018-05-07 | 2022-05-17 | Alnylam Pharmaceuticals Inc | Entrega extra-hepática |
| WO2019217997A1 (en) * | 2018-05-14 | 2019-11-21 | Murdoch University | Methods for treating vegf-related conditions |
| EP3833763A4 (en) | 2018-08-10 | 2023-07-19 | University of Massachusetts | MODIFIED OLIGONUCLEOTIDES FOR TARGETING SNPS |
| WO2020041769A1 (en) | 2018-08-23 | 2020-02-27 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| WO2020150636A1 (en) | 2019-01-18 | 2020-07-23 | University Of Massachusetts | Dynamic pharmacokinetic-modifying anchors |
| KR20220047989A (ko) | 2019-08-09 | 2022-04-19 | 유니버시티 오브 매사추세츠 | Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드 |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| JP2023514190A (ja) * | 2020-02-10 | 2023-04-05 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Ｖｅｇｆ－ａ発現をサイレンシングするための組成物および方法 |
| EP4157289A4 (en) | 2020-05-26 | 2024-06-26 | University Of Massachusetts | Synthetic oligonucleotides having regions of block and cluster modifications |
| BR112023026862A2 (pt) | 2021-06-23 | 2024-03-05 | Beth Israel Deaconess Medical Ct Inc | Compostos de oligonucleotídeos anti-flt1 otimizados para tratamento de pré-eclâmpsia e outros distúrbios angiogênicos |
| US11912997B2 (en) | 2022-06-15 | 2024-02-27 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use |
| WO2025140190A1 (en) * | 2023-12-25 | 2025-07-03 | Microbio (Shanghai) Co., Ltd. | Carbon chain-modified nucleic acids and uses thereof for bacterial cell delivery |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US8202979B2 (en) * | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| DE10302421A1 (de) * | 2003-01-21 | 2004-07-29 | Ribopharma Ag | Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit |
| ES2775525T3 (es) * | 2003-09-09 | 2020-07-27 | Geron Corp | Oligonucleótidos modificados para la inhibición de la telomerasa |
| US20050277610A1 (en) * | 2004-03-15 | 2005-12-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| AU2005323437B2 (en) * | 2004-04-30 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a C5-modified pyrimidine |
| WO2007022506A2 (en) * | 2005-08-18 | 2007-02-22 | University Of Massachusetts | Methods and compositions for treating neurological disease |
-
2008
- 2008-10-23 TW TW097140644A patent/TW200927177A/zh unknown
- 2008-10-24 WO PCT/JP2008/069829 patent/WO2009054551A2/en not_active Ceased
- 2008-10-24 SG SG2012075784A patent/SG185295A1/en unknown
- 2008-10-24 BR BRPI0818846 patent/BRPI0818846A2/pt not_active IP Right Cessation
- 2008-10-24 AU AU2008314860A patent/AU2008314860B2/en not_active Ceased
- 2008-10-24 MX MX2010004452A patent/MX2010004452A/es active IP Right Grant
- 2008-10-24 CN CN200880113141A patent/CN101835497A/zh active Pending
- 2008-10-24 NZ NZ584509A patent/NZ584509A/xx not_active IP Right Cessation
- 2008-10-24 AR ARP080104637A patent/AR069019A1/es unknown
- 2008-10-24 CN CN201510170411.XA patent/CN104726458A/zh active Pending
- 2008-10-24 JP JP2010516104A patent/JP5887648B2/ja not_active Expired - Fee Related
- 2008-10-24 EP EP08841497A patent/EP2217284A2/en not_active Withdrawn
- 2008-10-24 UA UAA201006211A patent/UA104131C2/uk unknown
- 2008-10-24 US US12/738,797 patent/US8981074B2/en not_active Expired - Fee Related
- 2008-10-24 KR KR1020107011095A patent/KR20100106314A/ko not_active Ceased
- 2008-10-24 RU RU2010120715/10A patent/RU2489167C2/ru not_active IP Right Cessation
- 2008-10-24 CA CA2703496A patent/CA2703496A1/en not_active Abandoned
-
2010
- 2010-04-07 ZA ZA2010/02427A patent/ZA201002427B/en unknown
- 2010-04-11 IL IL204992A patent/IL204992A/en not_active IP Right Cessation
- 2010-04-23 CO CO10048045A patent/CO6270240A2/es not_active Application Discontinuation
-
2015
- 2015-11-09 JP JP2015219623A patent/JP2016028605A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CO6270240A2 (es) | 2011-04-20 |
| RU2010120715A (ru) | 2011-11-27 |
| SG185295A1 (en) | 2012-11-29 |
| US20100298411A1 (en) | 2010-11-25 |
| WO2009054551A2 (en) | 2009-04-30 |
| CA2703496A1 (en) | 2009-04-30 |
| CN104726458A (zh) | 2015-06-24 |
| CN101835497A (zh) | 2010-09-15 |
| NZ584509A (en) | 2012-08-31 |
| JP2016028605A (ja) | 2016-03-03 |
| MX2010004452A (es) | 2010-08-04 |
| JP5887648B2 (ja) | 2016-03-16 |
| ZA201002427B (en) | 2011-06-29 |
| IL204992A (en) | 2015-11-30 |
| JP2011500002A (ja) | 2011-01-06 |
| UA104131C2 (uk) | 2014-01-10 |
| AU2008314860A1 (en) | 2009-04-30 |
| EP2217284A2 (en) | 2010-08-18 |
| AU2008314860B2 (en) | 2014-01-30 |
| RU2489167C2 (ru) | 2013-08-10 |
| WO2009054551A3 (en) | 2010-01-28 |
| AR069019A1 (es) | 2009-12-23 |
| KR20100106314A (ko) | 2010-10-01 |
| IL204992A0 (en) | 2010-11-30 |
| TW200927177A (en) | 2009-07-01 |
| US8981074B2 (en) | 2015-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0818846A2 (pt) | Rna de fita dupla modificado por lipídeo tendo potente efeito de rna de interferência. | |
| BRPI0722079A2 (pt) | Pirimidinas 5,6-substituídas inibidoras de hiv | |
| BRPI0811718A2 (pt) | Derivados de 3,3-espiroindolinona | |
| NL1031741A1 (nl) | Purinederivaten. | |
| BRPI0810202A2 (pt) | Derivados de piridina | |
| BRPI0817503A2 (pt) | Derivados de purina substituídos por pirimidina | |
| BRPI0615433A2 (pt) | método de impressão | |
| BRPI0809992A2 (pt) | Derivados de pirrolopirimidina | |
| BRPI0812155A2 (pt) | derivados de espiroindolinona | |
| BRPI0814236A2 (pt) | Derivados de quinazolinamida | |
| BRPI0812518A2 (pt) | Derivados de indazolamida | |
| BRPI0910446A2 (pt) | rna modificado por lipídeo de flamento duplo tendo alto efeito de interferência de rna | |
| BRPI0807005A2 (pt) | Manta impressa e método de produção | |
| BRPI0917446A2 (pt) | derivados de acilaminobenzamida. | |
| BRPI0924081A2 (pt) | DERIVADOS DE 5- AMINO -2-(1-hIDROXI-ETIL)- TETRAHIDROPIRANO. | |
| BRPI0811094A2 (pt) | Derivados de heteroarilamida pirimidona | |
| BRPI0816679A2 (pt) | Derivados de ftalazinona. | |
| LU93092I2 (de) | Alemtuzumab | |
| BRPI0811214A2 (pt) | Derivados de pirazolona | |
| DE602006005328D1 (de) | Differentialgehäuse | |
| FR2902426B1 (fr) | Derives de cinnamoyl-piperazine | |
| BRPI0812827A2 (pt) | Derivados de macrolactona | |
| BRPI0812816A2 (pt) | Derivados de sulfonil-quinolina | |
| AT503251A3 (de) | Doppeldifferentialanordnung | |
| BRPI0913181A2 (pt) | infecções por micobactérica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/54 (2017.01) |